New stem cell treatment darvadstrocel has not been approved by The National Institute for Health and Care Excellence (NICE) to treat complex perianal fistulas for use in the NHS.
NICE rules against Darvadstrocel
Perianal fistulas in people with Crohn’s Disease can be extremely debilitating, causing intense pain and discomfort and meaning even tasks such as sitting down can be difficult.
Currently there are limited treatment options available for complex perianal fistulas in adults with non-active/mild Crohn’s Disease who have not responded to conventional therapies (e.g. immunosuppressants / antibiotics) or biological therapies (e.g. infliximab / adalimumab).
Therefore, we are disappointed that NICE has chosen not to recommend this innovative stem cell treatment which could offer hope for those affected, as the current options available to treat perianal fistulas are limited and have varying degrees of success.
People often need to undergo multiple surgeries as part of the healing process, which can have a large impact on the individual both physically and psychologically. Furthermore, surgery involves risks including recurring symptoms and faecal incontinence.
NICE has chosen not to recommend darvadstrocel as the trial evidence has not shown sufficient clinical and cost effectiveness over time. For more information on their decision, please see the NICE Final Appraisal Determination. This guidance will be considered for review in 3 years’ time.
We are disappointed with NICE’s decision not to recommend the stem cell treatment darvadstrocel. There is significant unmet need and this treatment would offer a new option for people living with perianal fistulas alongside the debilitating nature of Crohn's Disease. We value the support of those living with a fistula and their carers who submitted evidence in response to our call out. Although darvadstrocel has not been recommended, we thank you for your evidence which helped greatly in informing our submission to NICE.
NICE’s decision to deny approval for darvadstrocel highlights the need for further research into perianal fistulas and treatment options.
One such project is being undertaken at Kings College London, where researchers are looking for people to take part in a study titled CAFQoL. This is assessing the experience of patients who have lived or a living with a perianal fistula.
This drug is currently being considered in Scotland by the Scottish Medical Consortium (SMC) and will be discussed within a Patient and Clinician Engagement (PACE) group in November.
- Find out more information about living with a fistula
Read our latest news
Catch up on the latest news from Crohn’s & Colitis UK
Helpline Service
Temporary closure - 10/06/2026
Our Helpline will be closed from Wednesday 10 June and will reopen at 10am on Monday 15 June.
We may be closed but we have lots of information here on our website.
If you need urgent medical advice you can call NHS 111 or in Northern Ireland phone your local Phone First. In an emergency call 999 or go to your nearest A&E.
If you need emotional support the Samaritans are available 24 hours a day, 7 days a week on 116 123.
We know it can be difficult to live with, or support someone living with Crohn’s or Colitis. But we’re with you. We can give you the right information and support at the right time.
We’re here for everyone.
How Can We Help?
- We can help you understand Crohn’s and Colitis
- Listen and talk about living with IBD
- Help you connect with others in the Crohn’s and Colitis community
- Give you contact details of specialist organisations
- We can support you to live well with Crohn’s or Colitis and provide up-to-date, evidence-based information
Please be aware we’re not medically or legally trained. We cannot provide detailed financial or benefits advice or specialist emotional support.
Please contact us via telephone, email or LiveChat - 10am to 3pm, Monday to Friday (except English bank holidays).
If you need specific medical advice about your condition, your GP or IBD team will be best placed to help.